Log in to save to my catalogue
Log in to save to my catalogue

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 s...

| Ask | Become a Library member

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 s...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2132223711

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

About this item

Publication information

Publisher

England: Elsevier Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

SummaryBackgroundLorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse th...

Alternative Titles

Full title

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2132223711

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2132223711

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(18)30649-1

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections